Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.

Gandotra C, Clark J, Liu Q, Senatore FF, Rose M, Zhang J, Stockbridge NL. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. Ther Innov Regul Sci. 2022 01; 56(1):4-7.

View in: PubMed

subject areas

Benzimidazoles
Biphenyl Compounds
Heart Failure
Humans
Spironolactone
Stroke Volume
Tetrazoles
United States
United States Food and Drug Administration
Ventricular Function, Left

authors with profiles

Charu Gandotra

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support